DAAN Biotherapeutics develops immune cell therapies for lung cancer using T Cell Receptors and natural killer (NK) cells to enhance treatment efficacy. The company addresses the limitations of existing therapies by providing targeted cell therapies, antibodies, and small molecule inhibitors to improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Existing lung cancer therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, often have limited efficacy and can result in poor patient outcomes. Natural killer (NK) cell treatments currently available have a restricted application range.
Solution
DAAN Biotherapeutics is developing novel immune cell therapies for lung cancer, utilizing T cell receptors (TCRs) expressed on natural killer (NK) cells to enhance treatment effectiveness. This approach aims to overcome the limitations of current therapies by providing targeted cell therapies designed to improve patient outcomes. The company focuses on research and development of cell therapies, antibodies, and small molecule inhibitors for cancer treatment.
Target Audience
The primary target audience includes cancer patients, particularly those with lung cancer, and healthcare providers seeking more effective treatment options.
Features
- Development of NK cell therapies expressing T cell receptors (TCRs) for targeted lung cancer treatment.
- Research and development of cell therapies, antibodies, and small molecule inhibitors.
- Overcoming limitations of tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors.